Heterogeneidad del tumor primario en la PET/TC con [68Ga]Ga-PSMA previa al tratamiento para la predicción de la recurrencia bioquímica en el cáncer de próstata

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular Pub Date : 2024-11-01 DOI:10.1016/j.remn.2024.500032

S. Gülbahar Ateş , B.B. Demirel , E. Kekilli , E. Öztürk , G. Uçmak

{"title":"Heterogeneidad del tumor primario en la PET/TC con [68Ga]Ga-PSMA previa al tratamiento para la predicción de la recurrencia bioquímica en el cáncer de próstata","authors":"S. Gülbahar Ateş , B.B. Demirel , E. Kekilli , E. Öztürk , G. Uçmak","doi":"10.1016/j.remn.2024.500032","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>The aim of this study is to research the value of the texture analysis of primary tumors in pre-treatment [68Ga]Ga-PSMA PET in the prediction of the development of biochemical recurrence (BCR) in prostate cancer patients who underwent definitive therapies.</div></div><div><h3>Methods</h3><div>Fifty-one patients with prostate adenocarcinoma who had a pre-treatment [68Ga]Ga-PSMA-11 PET/CT and underwent definitive radiotherapy (RT) or radical prostatectomy (RP) were included in the study. Demographics, clinicopathologic features, the presence of BCR, and the last follow-up date of patients were recorded. Textural and conventional PET parameters (maximum standardized uptake value (SUVmax), total lesion-PSMA (TL-PSMA), and PSMA-tumor volume (PSMA-TV)) were obtained from PET/CT images using LifeX program. Parameters were grouped using the Youden index in ROC analysis. Factors predicting the BCR were determined using Cox regression analyses.</div></div><div><h3>Results</h3><div>Twenty-nine (56.9%) patients have received primary curative RT, while the remaining 22 (43.1%) patients have undergone RP. 5 (22.7%) patients with RP and 3 (10.3%) patients with curative RT have developed BCR during the follow-up. INTENSITY-BASED-minimum grey level (<em>P</em>=.050), GLCM-sum variance (<em>P</em>=.019), and GLCM-cluster prominence (<em>P</em>=.050) were associated with BCR in univariate analysis. INTENSITY-BASED-minimum grey level (<em>P</em>=.009) and GLCM-sum variance (<em>P</em>=.004) were found as independent predictors of BCR in the multivariate analysis.</div></div><div><h3>Conclusion</h3><div>Tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET is associated with a high risk of BCR in PCa patients who underwent definitive therapies.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500032"},"PeriodicalIF":1.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Medicina Nuclear E Imagen Molecular","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2253654X24000404","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

The aim of this study is to research the value of the texture analysis of primary tumors in pre-treatment [68Ga]Ga-PSMA PET in the prediction of the development of biochemical recurrence (BCR) in prostate cancer patients who underwent definitive therapies.

Methods

Fifty-one patients with prostate adenocarcinoma who had a pre-treatment [68Ga]Ga-PSMA-11 PET/CT and underwent definitive radiotherapy (RT) or radical prostatectomy (RP) were included in the study. Demographics, clinicopathologic features, the presence of BCR, and the last follow-up date of patients were recorded. Textural and conventional PET parameters (maximum standardized uptake value (SUVmax), total lesion-PSMA (TL-PSMA), and PSMA-tumor volume (PSMA-TV)) were obtained from PET/CT images using LifeX program. Parameters were grouped using the Youden index in ROC analysis. Factors predicting the BCR were determined using Cox regression analyses.

Results

Twenty-nine (56.9%) patients have received primary curative RT, while the remaining 22 (43.1%) patients have undergone RP. 5 (22.7%) patients with RP and 3 (10.3%) patients with curative RT have developed BCR during the follow-up. INTENSITY-BASED-minimum grey level (P=.050), GLCM-sum variance (P=.019), and GLCM-cluster prominence (P=.050) were associated with BCR in univariate analysis. INTENSITY-BASED-minimum grey level (P=.009) and GLCM-sum variance (P=.004) were found as independent predictors of BCR in the multivariate analysis.

Conclusion

Tumor heterogeneity on pre-treatment [68Ga]Ga-PSMA PET is associated with a high risk of BCR in PCa patients who underwent definitive therapies.

查看原文本刊更多论文

用于预测前列腺癌生化复发的治疗前[68Ga]Ga-PSMA PET/CT 原发肿瘤异质性

目的研究治疗前[68Ga]Ga-PSMA PET中原发肿瘤的纹理分析在预测接受明确治疗的前列腺癌患者发生生化复发（BCR）中的价值。方法纳入51例接受治疗前[68Ga]Ga-PSMA-11 PET/CT检查并接受明确放疗（RT）或根治性前列腺切除术（RP）的前列腺腺癌患者。研究人员记录了患者的人口统计学特征、临床病理学特征、是否存在 BCR 以及最后一次随访日期。利用LifeX程序从PET/CT图像中获取纹理参数和常规PET参数（最大标准化摄取值（SUVmax）、总病灶-PSMA（TL-PSMA）和PSMA-肿瘤体积（PSMA-TV））。在 ROC 分析中使用尤登指数对参数进行分组。结果29例（56.9%）患者接受了初治RT，其余22例（43.1%）患者接受了RP。5例（22.7%）RP患者和3例（10.3%）根治性RT患者在随访期间出现了BCR。INTENSITY-BASED-minimum grey level（P=.050）、GLCM-sum variance（P=.019）和 GLCM-cluster prominence（P=.050）在单变量分析中与 BCR 相关。结论治疗前[68Ga]Ga-PSMA PET 显示的肿瘤异质性与接受明确疗法的 PCa 患者发生 BCR 的高风险有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Espanola De Medicina Nuclear E Imagen Molecular RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

1.10

自引率

16.70%

发文量

审稿时长

24 days

期刊介绍： The Revista Española de Medicina Nuclear e Imagen Molecular (Spanish Journal of Nuclear Medicine and Molecular Imaging), was founded in 1982, and is the official journal of the Spanish Society of Nuclear Medicine and Molecular Imaging, which has more than 700 members. The Journal, which publishes 6 regular issues per year, has the promotion of research and continuing education in all fields of Nuclear Medicine as its main aim. For this, its principal sections are Originals, Clinical Notes, Images of Interest, and Special Collaboration articles.